- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 11, Issue 28, 2005
Current Pharmaceutical Design - Volume 11, Issue 28, 2005
Volume 11, Issue 28, 2005
-
-
Editorial [Hot Topic: Cell-Penetrating Peptides, Mechanisms and Applications (Executive Editor: Ulo Langel)]
By Ulo LangelThis special issue of Current Pharmaceutical Design is dedicated to cell-penetrating peptides, CPPs, their mechanisms and applications. It is divided into seven chapters in which several aspects of cell-penetrating peptides are updated. This issue was compiled in November 2004 and reflects the concise summary of CPP research in recent 10 years since the first CPP, pAntennapedia (later named penetratin) was discovered by Alai Read More
-
-
-
Cell-Penetrating Peptides: Mechanisms and Applications
Authors: S. El-Andaloussi, T. Holm and U. LangelA major obstacle in the development of new therapeutic agents is the low bioavailability of hydrophilic substances. Drugs that bind to intracellular targets must penetrate the lipid bilayer surrounding the cell in order to exert their effect. A relatively new research area that addresses this problem by introducing novel transport peptides that facilitate the cellular penetration of potential drugs has emerged. These peptides p Read More
-
-
-
Endocytosis and Cationic Cell-Penetrating Peptides - A Merger of Concepts and Methods
Authors: M. Fotin-Mleczek, R. Fischer and R. BrockWith the identification of fixation as a major source of artefacts in the cell biological research on cellpenetrating peptides (CPPs), the past two years have witnessed a dramatic development in the CPP field. At least for some of these molecules, endocytosis is now considered to be the major if not the exclusive route of cellular import. However, endocytosis comprises a variety of different pathways with very different implications fo Read More
-
-
-
Interactions of Primary Amphipathic Cell Penetrating Peptides with Model Membranes: Consequences on the Mechanisms of Intracellular Delivery of Therapeutics
Authors: S. Deshayes, M. C. Morris, G. Divita and F. HeitzThis review focuses on two peptides, MPG and Pep-1, which facilitate the transfer of nucleic acids and proteins, respectively, into subcellular compartments. We have investigated the interactions between these two carrier peptides and model membrane systems as well as the conformational consequences of these interactions. Studies performed with lipid monolayers at the air - water interface have enabled id Read More
-
-
-
Conjugates of Oligonucleotides and Analogues with Cell Penetrating Peptides as Gene Silencing Agents
Authors: T. S. Zatsepin, J. J. Turner, T. S. Oretskaya and M. J. GaitThe review describes key aspects of the synthesis and biological activities of conjugates of oligonucleotides and their analogues with synthetic peptides, in particular aimed towards gene silencing applications. The common methods of synthesis of oligonucleotide-peptide conjugates (OPCs) and PNA-peptide conjugates (PPCs) are described, which include both total solid-phase and fragment coupling approaches. In addition, v Read More
-
-
-
Vascular Homing Peptides with Cell-Penetrating Properties
Authors: E. Ruoslahti, T. Duza and L. ZhangIn vivo screening of phage-displayed peptide libraries has revealed extensive molecular heterogeneity in the blood vessels of individual normal tissues and shown that pathological lesions put their signature on the vasculature. In tumors, both blood and lymphatic vessels differ from normal vessels. Moreover, the molecular changes in the vasculature parallel progression in tumor development, hence making the vessels in pr Read More
-
-
-
Calcitonin-Derived Carrier Peptides
Authors: I. Neundorf and A. G. Beck-SickingerThe rescent discovery of carrier peptides offers new opportunities to translocate several bioactive molecules into the cytoplasm. Previous studies have shown that human calcitonin (hCT) and selected C-terminal sequences translocate in nasal epithelium. Moreover, the hCT(9-32) fragment was found to internalize efficiently a number of substances like fluorophores, nucleic acids or the enhanced green fluorescent protein (EGFP) Read More
-
-
-
Bioplex Technology: Novel Synthetic Gene Delivery Pharmaceutical Based on Peptides Anchored to Nucleic Acids
Authors: O. E. Simonson, M. G. Svahn, E. Tornquist, K. E. Lundin and C. I.E. SmithNon-viral gene delivery is an important approach in order to establish safe in vivo gene therapy in the clinic. Although viral vectors currently exhibit superior gene transfer efficacy, the safety aspect of viral gene delivery is a concern. In order to improve non-viral in vivo gene delivery we have designed a pharmaceutical platform called Bioplex (biological complex). The concept of Bioplex is to link functional entities via hybridisin Read More
-
-
-
Direct Interaction of Dietary Lipids Carried in Chylomicron Remnants with Cells of the Artery Wall: Implications for Atherosclerosis Development
Authors: K. M. Botham, E. Bravo, J. Elliott and C. P.D. Wheeler-JonesThe development of atherosclerotic lesions in the artery wall is a complex process involving the endothelium, lipid engorged macrophages (foam cells) and smooth muscle cells. In recent years it has become clear that chylomicron remnants, the lipoproteins which carry lipids of dietary origin in the blood, are strongly atherogenic, and there is increasing evidence to indicate that this is due to direct interaction of the remnant p Read More
-
-
-
Hepatotoxicity of Antiretroviral Drugs
Authors: N. Abrescia, M. D'Abbraccio, M. Figoni, A. Busto, A. Maddaloni and M. D. MarcoThe use of highly active antiretroviral therapy (HAART) has significantly slowed the HIV disease progression. However, adverse effects are now a limiting cause of HAART benefit in a substantial proportion of patients. Particularly hepatotoxicity which is a common complication occurring during every HAART regimen. All antiretroviral (ARV) drugs classes, Nucleoside/Nucleotide reverse transcriptase inhibitors (NRTI), non-Nucleosid Read More
-
-
-
Oral and Intravenous Ibandronate in the Management of Postmenopausal Osteoporosis: A Comprehensive Review
More LessConvenient strategies are needed for postmenopausal osteoporosis management. Current oral bisphosphonates are effective and generally well tolerated, but are hampered by strict dosing requirements. Less frequent dosing schedules are expected to improve adherence to therapy and hence outcomes. Ibandronate is a potent, nitrogen-containing bisphosphonate in ongoing clinical development exploring its potential to Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
